MCID: EST002
MIFTS: 44

Estrogen-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060076

Summaries for Estrogen-Receptor Negative Breast Cancer

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to estrogen-receptor positive breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Bevacizumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and lymph node, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor positive breast cancer 30.2 ERBB2 ESR1 FOXA1 PGR
2 breast cancer 29.3 AR BRCA1 EGF ERBB2 ESR1 FOXA1
3 vulvar syringoma 10.5 ESR1 PGR
4 vestibular gland benign neoplasm 10.5 ESR1 PGR
5 lung leiomyoma 10.5 ESR1 PGR
6 bartholin's gland adenoma 10.5 ESR1 PGR
7 vulvar benign neoplasm 10.5 ESR1 PGR
8 scirrhous adenocarcinoma 10.5 ERBB2 PGR
9 breast apocrine carcinoma 10.5 ERBB2 PGR
10 trigonitis 10.5 ESR1 PGR
11 vulvar leiomyoma 10.5 ESR1 PGR
12 postmenopausal atrophic vaginitis 10.5 AR ESR1
13 comedo carcinoma 10.5 ERBB2 ESR1
14 predominantly cortical thymoma 10.5 ESR1 PGR
15 progesterone resistance 10.5 ESR1 PGR
16 intracystic papillary adenoma 10.5 ERBB2 PGR
17 cribriform carcinoma 10.5 ESR1 PGR
18 progesterone-receptor negative breast cancer 10.5 ERBB2 PGR
19 bartholin's gland benign neoplasm 10.5 ESR1 PGR
20 gastric signet ring cell adenocarcinoma 10.5 ESR1 PGR
21 endometrial mucinous adenocarcinoma 10.5 ESR1 PGR
22 sebaceous adenoma 10.5 EGF ESR1
23 adenoid basal cell carcinoma 10.5 ESR1 PGR
24 deep angioma 10.4 ESR1 PGR
25 cervical carcinosarcoma 10.4 ESR1 PGR
26 calcifying aponeurotic fibroma 10.4 EGF PGR
27 corneal abscess 10.4 AR PGR
28 intramuscular hemangioma 10.4 ESR1 PGR
29 uterine body mixed cancer 10.4 ERBB2 PGR
30 estrogen excess 10.4 ESR1 PGR
31 breast squamous cell carcinoma 10.4 ERBB2 PGR
32 mammographic density 10.4 ESR1 PGR
33 retinitis pigmentosa 47 10.4 ESR1 PGR
34 paget disease, extramammary 10.4 AR ERBB2
35 epispadias 10.4 EGF ERBB2
36 endometrial squamous cell carcinoma 10.4 AR ESR1 PGR
37 gender identity disorder 10.3 AR ESR1 PGR
38 glassy cell carcinoma of the cervix 10.3 ERBB2 ESR1 PGR
39 breast scirrhous carcinoma 10.3 ERBB2 ESR1 PGR
40 microglandular adenosis 10.3 ERBB2 PGR
41 progesterone-receptor positive breast cancer 10.3 ERBB2 ESR1 PGR
42 adenomyosis 10.3 ESR1 PGR
43 prostatic hypertrophy 10.3 AR ESR1 PGR
44 breast benign neoplasm 10.3 ERBB2 ESR1 PGR
45 thoracic benign neoplasm 10.3 ERBB2 ESR1 PGR
46 uterine corpus cancer 10.3 ERBB2 ESR1 PGR
47 inflammatory breast carcinoma 10.3 ERBB2 ESR1 PGR
48 mixed cell type cancer 10.3 ERBB2 ESR1 PGR
49 vaginitis 10.3 AR CXCL8 ESR1
50 lipid-rich carcinoma 10.3 ERBB2 ESR1 PGR

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.06 ESR1 BRCA1 CCAR2 FOXA1 EGF ERBB2
2 endocrine/exocrine gland MP:0005379 10.03 FOXA1 EGF PGR ERBB2 AR ESR1
3 digestive/alimentary MP:0005381 10 FOXA1 EGF ERBB2 AR ESR1 BRCA1
4 immune system MP:0005387 9.97 ESR1 BRCA1 CCAR2 FOXA1 EGF AR
5 integument MP:0010771 9.87 ESR1 BRCA1 FOXA1 EGF PGR ERBB2
6 limbs/digits/tail MP:0005371 9.73 BRCA1 PGR ERBB2 AR ESR1 WNT5A
7 neoplasm MP:0002006 9.7 FOXA1 CCAR2 PGR ERBB2 AR ESR1
8 normal MP:0002873 9.5 ESR1 BRCA1 EGF PGR ERBB2 AR
9 reproductive system MP:0005389 9.17 ESR1 BRCA1 EGF ERBB2 AR PGR

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
6
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
7
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
8
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
9
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
10
Goserelin Approved Phase 3 65807-02-5 5311128 47725
11
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
12
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
13
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
14
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
15
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
18
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
19
Lapatinib Approved March 2007, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
20
Doxil Approved June 1999 Phase 3,Phase 2 31703
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Angiogenesis Inhibitors Phase 3,Phase 2
23 Angiogenesis Modulating Agents Phase 3,Phase 2
24 Anti-Bacterial Agents Phase 3,Phase 2
25 Antibiotics, Antitubercular Phase 3,Phase 2
26 Antimetabolites Phase 3,Phase 2
27 Antimetabolites, Antineoplastic Phase 3,Phase 2
28 Antirheumatic Agents Phase 3,Phase 2
29 Estrogens Phase 3,Phase 2,Phase 1
30 Hormone Antagonists Phase 3,Phase 2,Phase 1
31 Hormones Phase 3,Phase 2,Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
33 Immunosuppressive Agents Phase 3,Phase 2
34 Progestins Phase 3,Phase 2,Phase 1
35 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
36 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
37 Albumin-Bound Paclitaxel Phase 2, Phase 3
38 Anti-Infective Agents Phase 2, Phase 3
39 Antimitotic Agents Phase 2, Phase 3, Phase 1
40 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1
41 Antiviral Agents Phase 2, Phase 3
42 Antineoplastic Agents, Hormonal Phase 3,Phase 2
43 Dermatologic Agents Phase 3,Phase 2
44 Folic Acid Antagonists Phase 3,Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
46 Vitamin B Complex Phase 3,Phase 2
47 triamcinolone acetonide Phase 3
48 Triamcinolone diacetate Phase 3
49 Triamcinolone hexacetonide Phase 3
50 Folate Nutraceutical Phase 3,Phase 2

Interventional clinical trials:

(show all 50)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3 lapatinib ditosylate
3 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel 125 mg/m2;Carboplatin AUC 2;gemcitabine 1000 mg
4 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
5 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
6 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3 Cyclophosphamide;Methotrexate
7 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
8 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
9 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
10 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
11 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
12 Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer Completed NCT00239343 Phase 2 gefitinib
13 Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
14 Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Completed NCT00559507 Phase 2 saracatinib
15 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
16 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
17 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
18 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
19 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Completed NCT00834678 Phase 1, Phase 2 bendamustine;erlotinib;Maintenance erlotinib
20 Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00424203 Phase 2 AC regimen;cyclophosphamide;doxorubicin hydrochloride
21 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Recruiting NCT01471106 Phase 2 Dasatinib
22 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer Recruiting NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
23 Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
24 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting NCT01037790 Phase 2 PD-0332991
25 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Active, not recruiting NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
26 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Active, not recruiting NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
27 Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Active, not recruiting NCT01372579 Phase 2 eribulin mesylate;carboplatin
28 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting NCT01463072 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
29 Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Active, not recruiting NCT01147016 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
30 GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Terminated NCT01918306 Phase 1, Phase 2 cisplatin;GDC -0941
31 Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Terminated NCT01234532 Phase 2 entinostat;anastrozole
32 RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Terminated NCT01217411 Phase 1, Phase 2 Gamma-secretase/Notch signalling pathway inhibitor RO4929097
33 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
34 Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer Withdrawn NCT01100489 Phase 2
35 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
36 Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
37 Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
38 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
39 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
40 Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 Unknown status NCT01666171 metformin hydrochloride
41 Study of Tumor and Blood Samples From Women With Breast Cancer Unknown status NCT00897728
42 Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer Completed NCT00900133
43 Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer Completed NCT00870168 chemotherapy
44 TC Avastin. ICORG 08-10, V6 Completed NCT00911716 cyclophosphamide;docetaxel
45 Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Completed NCT00115505
46 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Completed NCT00072293
47 Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
48 Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer Completed NCT00068328
49 Assessment of Candidate Protein Expression in Breast Cancer Specimens Recruiting NCT00918892
50 Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer Terminated NCT00503841 erlotinib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

38
Breast, Brain, Lymph Node, Bone, T Cells, Colon, Endothelial

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 183)
# Title Authors Year
1
Associations between Diet Quality Scores and Risk of Postmenopausal Estrogen Receptor-Negative Breast Cancer: A Systematic Review. ( 29378048 )
2018
2
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention. ( 28877935 )
2017
3
Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. ( 28957356 )
2017
4
Effect of 17I^-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. ( 29133279 )
2017
5
Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit I^-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer. ( 29069648 )
2017
6
WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. ( 28469783 )
2017
7
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. ( 29058716 )
2017
8
Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. ( 27988896 )
2017
9
Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. ( 28263391 )
2017
10
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer. ( 28881566 )
2017
11
Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. ( 29141994 )
2017
12
AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. ( 28238761 )
2017
13
Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. ( 29087320 )
2017
14
Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. ( 28280355 )
2017
15
Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. ( 26926102 )
2016
16
Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. ( 27431462 )
2016
17
Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. ( 27328114 )
2016
18
The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. ( 27656887 )
2016
19
Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. ( 27594435 )
2016
20
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. ( 28039445 )
2016
21
Life history theory and breast cancer risk: methodological and theoretical challenges: Response to "Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?". ( 26874356 )
2016
22
Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II. ( 27294610 )
2016
23
Is estrogen receptor negative breast cancer risk associated with a fast life history strategy? ( 26781544 )
2016
24
Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. ( 26850467 )
2016
25
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. ( 27167193 )
2016
26
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. ( 26648459 )
2016
27
Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells. ( 26220629 )
2015
28
Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. ( 25955347 )
2015
29
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 26621491 )
2015
30
Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status. ( 26339363 )
2015
31
Interleukin-8 upregulates integrin I^3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-I_B pathway. ( 25979232 )
2015
32
Induction of apoptosis and oxidative stress in estrogen receptor-negative breast cancer, MDA-MB231 cells, by ethanolic mango seed extract. ( 25881293 )
2015
33
Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women. ( 26085483 )
2015
34
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. ( 25849327 )
2015
35
Nitric Oxide-Releasing Aspirin Suppresses NF-I_B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( 26184135 )
2015
36
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 25720324 )
2015
37
N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation. ( 26279450 )
2015
38
NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. ( 26351264 )
2015
39
Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. ( 25852060 )
2015
40
In Vitro and In Silico Evaluation of NF-I_B Targeted Costunolide Action on Estrogen Receptor-Negative Breast Cancer Cells-A Comparison with Normal Breast Cells. ( 24733523 )
2014
41
Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. ( 24850180 )
2014
42
Expression of Reactive Oxygen Species-Related Proteins according to Androgen and HER-2 Status in Estrogen Receptor-Negative Breast Cancer. ( 25322848 )
2014
43
Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer. ( 25140630 )
2014
44
A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer. ( 25417701 )
2014
45
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. ( 24678876 )
2014
46
A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. ( 24523857 )
2014
47
The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. ( 25275589 )
2014
48
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. ( 24829621 )
2014
49
Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women. ( 24718280 )
2014
50
Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. ( 25081341 )
2014

Variations for Estrogen-Receptor Negative Breast Cancer

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Pathways for Estrogen-Receptor Negative Breast Cancer

GO Terms for Estrogen-Receptor Negative Breast Cancer

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.8 EGF ERBB2 PTPRA

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.93 AR BRCA1 ESR1 FOXA1 PGR WNT5A
2 positive regulation of transcription, DNA-templated GO:0045893 9.88 AR BRCA1 EGF ESR1 WNT5A
3 positive regulation of gene expression GO:0010628 9.87 AR BRCA1 EGF ERBB2
4 regulation of transcription by RNA polymerase II GO:0006357 9.83 AR BRCA1 ERBB2 ESR1 FOXA1
5 transcription initiation from RNA polymerase II promoter GO:0006367 9.77 AR ESR1 PGR
6 positive regulation of angiogenesis GO:0045766 9.75 BRCA1 CXCL8 WNT5A
7 male gonad development GO:0008584 9.71 AR ESR1 WNT5A
8 regulation of cell motility GO:2000145 9.61 EGF ERBB2
9 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.61 EGF WNT5A
10 dopaminergic neuron differentiation GO:0071542 9.58 FOXA1 WNT5A
11 uterus development GO:0060065 9.56 ESR1 WNT5A
12 negative regulation of ERBB signaling pathway GO:1901185 9.55 EGF ERBB2
13 positive regulation of transcription by RNA polymerase III GO:0045945 9.52 AR ERBB2
14 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.51 AR FOXA1
15 steroid hormone mediated signaling pathway GO:0043401 9.5 AR ESR1 PGR
16 vagina development GO:0060068 9.49 ESR1 WNT5A
17 positive regulation of cell-cell adhesion mediated by cadherin GO:2000049 9.4 FOXA1 WNT5A
18 prostate gland epithelium morphogenesis GO:0060740 9.37 AR FOXA1
19 epithelial cell proliferation involved in mammary gland duct elongation GO:0060750 9.26 ESR1 WNT5A
20 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.16 AR PGR
21 lateral sprouting involved in mammary gland duct morphogenesis GO:0060599 8.96 AR WNT5A
22 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1
23 transcription, DNA-templated GO:0006351 10.14 AR BRCA1 CCAR2 ERBB2 ESR1 FOXA1

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.71 AR ESR1 FOXA1 PGR
2 transcription regulatory region DNA binding GO:0044212 9.62 AR BRCA1 FOXA1 WNT5A
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.61 EGF ERBB2 PTPRA
4 ATPase binding GO:0051117 9.54 AR ESR1 PGR
5 steroid hormone receptor activity GO:0003707 9.43 AR ESR1 PGR
6 enzyme binding GO:0019899 9.35 AR BRCA1 CCAR2 ESR1 PGR
7 nuclear receptor activity GO:0004879 9.33 AR ESR1 PGR
8 steroid binding GO:0005496 8.8 AR ESR1 PGR

Sources for Estrogen-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....